Treatment with Antihistamines and the Risk of Liver Cancer in Patients with Viral Hepatitis: A Multi-Center Cohort Study
- PMID: 38932232
- PMCID: PMC11209559
- DOI: 10.3390/v16060940
Treatment with Antihistamines and the Risk of Liver Cancer in Patients with Viral Hepatitis: A Multi-Center Cohort Study
Abstract
Background: The effects of antihistamines on cancer risk and prognosis have been inconsistent across cancers. The aim of this multi-center cohort study was to investigate the association between antihistamine use and the risk of liver cancer in individuals with viral hepatitis. Methods: This multi-center cohort study included individuals diagnosed with hepatitis B or hepatitis C between January 2008 and March 2022. For antihistamine-treated patients, the index date was the date of antihistamine prescription, and for non-users, it was the date of hepatitis diagnosis. Participants were followed for five years, with the primary outcome of interest being new-onset liver cancer. The incidence rate and the adjusted hazard ratio (aHR) along with its 95% confidence interval (CI) of the outcome were calculated. Subgroup analyses were conducted, stratified by types of viral hepatitis including hepatitis C and hepatitis B. An additional validation study was performed. Results: The study included a total of 7748 patients with viral hepatitis. The incidence rate was 12.58 per 1000 person-years in patients with viral hepatitis on antihistamines, compared to 3.88 per 1000 person-years in those without antihistamine use. After adjusting for factors including age, sex, body mass index (BMI), comorbidities, laboratory data of liver function tests, comedications, and the use of antiviral therapies, the risk of new-onset liver cancer was significantly higher in patients on antihistamines (aHR = 1.83, 95% CI, 1.28-2.60). In patients with hepatitis C, the incidence rate in the antihistamine group was 15.73 per 1000 person-years, while non-users had a rate of 4.79 per 1000 person-years. Patients with hepatitis C on antihistamines had a significantly higher risk of developing liver cancer (aHR = 3.24, 95% CI, 2.16-4.86). Conclusions: This multi-center cohort study reported an increased risk of liver cancer in patients with hepatitis B or hepatitis C treated with antihistamines. Long-term follow-up studies are warranted to validate the findings.
Keywords: antihistamine; hepatitis C; liver cancer; viral hepatitis.
Conflict of interest statement
All authors declare no conflicts of interest.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Effect of liver cirrhosis on metastasis in colorectal cancer patients: a nationwide population-based cohort study.Jpn J Clin Oncol. 2015 Feb;45(2):160-8. doi: 10.1093/jjco/hyu178. Epub 2014 Nov 6. Jpn J Clin Oncol. 2015. PMID: 25378650
-
Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007.J Viral Hepat. 2011 Jul;18(7):e232-41. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17. J Viral Hepat. 2011. PMID: 21692938
-
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.Semin Liver Dis. 2000;20(1):17-35. doi: 10.1055/s-2000-9505. Semin Liver Dis. 2000. PMID: 10895429 Review.
-
A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.Int J Epidemiol. 1998 Aug;27(4):574-8. doi: 10.1093/ije/27.4.574. Int J Epidemiol. 1998. PMID: 9758109
References
-
- Razavi-Shearer D., Gamkrelidze I., Nguyen M.H., Chen D.S., Van Damme P., Abbas Z., Abdulla M., Abou Rached A., Adda D., Aho I., et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol. 2018;3:383–403. doi: 10.1016/s2468-1253(18)30056-6. - DOI - PubMed
-
- Blach S., Terrault N.A., Tacke F., Gamkrelidze I., Craxi A., Tanaka J., Waked I., Dore G.J., Abbas Z., Abdallah A.R., et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study. Lancet Gastroenterol. Hepatol. 2022;7:396–415. doi: 10.1016/s2468-1253(21)00472-6. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical